logo-loader

Silence Therapeutics keen to be a world-leader in drug development

Published: 01:18 17 Oct 2017 AEDT

Ali Mortazavi, chief executive of Silence Therapeutics caught up with Proactive Investors following their announcement this week of Dr. Annalisa Jenkins as non-executive chair.

''2017 has really been a seminal year for drug development and RNAi in particular'', Mortazavi says.

Discussing Alnylam’s Patisiran drug, he says: ''They didn't just scrape through. It wasn't one of those drugs that just got there - this really heralds the moment  when RNA interference really can be a new modality in serious unmet needs''.

''2018 really for us is kind of a re-ignition of the science and the drug development side.''

''In the first 6 or 7 months of this year, we spent a lot of time talking about IP but we're really keen to establish Silence as a world leader in actually being able to develop  drugs''.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

3 hours, 26 minutes ago